AMZ-0026

AMZ-0026 is a proprietary, sustained-release formulation of dexamethasone phosphate developed by Amzell, a subsidiary of Amneal Pharmaceuticals, for the treatment of Meniere's disease. The drug is administered via intratympanic injection, a localized delivery method that targets the inner ear tissues directly. By utilizing a sustained-release delivery system, AMZ-0026 aims to provide prolonged therapeutic levels of the corticosteroid to the vestibular and cochlear systems, thereby reducing inflammation and alleviating the core symptoms of Meniere's disease, such as vertigo, tinnitus, and hearing loss. This localized approach is intended to maximize efficacy within the inner ear while minimizing the systemic side effects typically associated with oral or intravenous corticosteroid administration.

Other names

Dexamethasone phosphate sustained-releaseIntratympanic dexamethasone phosphate